EU launch of ECOVAXXIN® MS

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company marketing and developing branded veterinary products to improve livestock productivity and welfare, announces the commercial launch of ECOVAXXIN® MS, its poultry vaccine against Mycoplasma synoviae (M. synoviae), across the European Union (EU) with its official launch event in Madrid, Spain.

ECOVAXXIN® MS represents the first product from ECO's proprietary R&D pipeline to reach commercial market entry. The vaccine provides active immunisation of future layer and breeder chickens from four weeks of age, to reduce air-sac and foot-pad lesions and egg production losses caused by M. synoviae infections. The infection causes significant economic loss, particularly in laying hens, where egg production in affected layers can be reduced by 5-10%.

Andrew Buglass, Chief Commercial Officer of ECO Animal Health, commented: "ECOVAXXIN® MS is a best-in-class vaccine backed by an established EU commercial infrastructure and a network of committed distribution partners ready to reach producers at scale. We believe this will deliver meaningful clinical benefit for layer and breeder flocks across Europe and look forward to building on this commercial momentum across our launch markets."

ECO is leveraging its established commercial network, built for Aivlosin®, to deliver comprehensive market coverage with strategic distribution agreements in place across the major poultry markets in the EU, providing access to markets representing over 220 million layer-birds annually.

The Company is also progressing registration in USA, Latin American and Asian markets.